Expertise: Venture Capital
Vincent has more than 30 years of management experience in the biotechnology industry. He identifies and invests in new businesses and supports portfolio companies. Vincent is on the boards of Dynex Technologies, Hydra Biosciences, Magellan Diagnostics and Personalis, and has also served on the boards of Chiasma, Dicerna Pharmaceuticals and PrimeraDx. Before joining Abingworth he was Senior Vice President, Business Development, of Alnylam Pharmaceuticals (a former Abingworth portfolio company).
Previously, Vincent was at Millennium Pharmaceuticals where he held VP positions in business development, strategic planning and corporate communications. Earlier, he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia. He began his career in R&D at Amersham International. He has a BSc in Biochemistry and a PhD in Molecular Biology from University College London.